Peter McCulloch1. 1. Nuffield Department of Surgical Science, University of Oxford, Oxford, UK. peter.mcculloch@nds.ox.ac.uk
Abstract
PURPOSE: Like other branches of surgery, Urology has encountered major challenges in aligning the research processes by which new interventions are assessed with the principles of Evidence-Based Medicine. This article explains the IDEAL framework and recommendations and illustrates how they might affect the evaluation of current controversial urological procedures. METHODS: From an inside perspective, we provide an overview of the efforts of the IDEAL Working Group to date with special emphasis on the field of Urology. RESULTS: There are clear differences between drugs and interventions in the natural history of innovations. Since the conventional framework for conducting trials of new treatments is largely based on the former, the evaluation of surgical innovations using the same template can encounter significant problems. Difficulties in performing randomized controlled trials of surgical techniques and the persistence of the case series as an important feature of the scientific literature have been the two most controversial aspects of this mismatch between the subject of research and the methodology used. The IDEAL framework provides a description of the process of innovation and development for surgical trials, and the associated recommendations provide a suggested alternative approach to developing study designs, which are appropriate for the specific problems of new techniques. CONCLUSIONS: IDEAL provides a new framework for surgical innovation that was developed with broad stakeholder input from the surgical community and is expected to have a transformative impact on the way that urologists perform clinical research.
PURPOSE: Like other branches of surgery, Urology has encountered major challenges in aligning the research processes by which new interventions are assessed with the principles of Evidence-Based Medicine. This article explains the IDEAL framework and recommendations and illustrates how they might affect the evaluation of current controversial urological procedures. METHODS: From an inside perspective, we provide an overview of the efforts of the IDEAL Working Group to date with special emphasis on the field of Urology. RESULTS: There are clear differences between drugs and interventions in the natural history of innovations. Since the conventional framework for conducting trials of new treatments is largely based on the former, the evaluation of surgical innovations using the same template can encounter significant problems. Difficulties in performing randomized controlled trials of surgical techniques and the persistence of the case series as an important feature of the scientific literature have been the two most controversial aspects of this mismatch between the subject of research and the methodology used. The IDEAL framework provides a description of the process of innovation and development for surgical trials, and the associated recommendations provide a suggested alternative approach to developing study designs, which are appropriate for the specific problems of new techniques. CONCLUSIONS: IDEAL provides a new framework for surgical innovation that was developed with broad stakeholder input from the surgical community and is expected to have a transformative impact on the way that urologists perform clinical research.
Authors: Jeffrey S Barkun; Jeffrey K Aronson; Liane S Feldman; Guy J Maddern; Steven M Strasberg; Douglas G Altman; Jeffrey S Barkun; Jane M Blazeby; Isabell C Boutron; W Bruce Campbell; Pierre-Alain Clavien; Jonathan A Cook; Patrick L Ergina; David R Flum; Paul Glasziou; John C Marshall; Peter McCulloch; Jon Nicholl; Bournaby C Reeves; Christoph M Seiler; Jonathan L Meakins; Deborah Ashby; Nick Black; John Bunker; Martin Burton; Marion Campbell; Kalipso Chalkidou; Iain Chalmers; Marc de Leval; Jon Deeks; Adrian Grant; Muir Gray; Roger Greenhalgh; Milos Jenicek; Sean Kehoe; Richard Lilford; Peter Littlejohns; Yoon Loke; Rajan Madhock; Kim McPherson; Peter Rothwell; Bill Summerskill; David Taggart; Parris Tekkis; Matthew Thompson; Tom Treasure; Ulrich Trohler; Jan Vandenbroucke Journal: Lancet Date: 2009-09-26 Impact factor: 79.321
Authors: Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell Journal: J Natl Cancer Inst Date: 2006-05-03 Impact factor: 13.506
Authors: Berrend G Muller; Daniel M de Bruin; Willemien van den Bos; Martin J Brandt; Juliette F Velu; Mieke T J Bus; Dirk J Faber; Dilara Savci; Patricia J Zondervan; Theo M de Reijke; Pilar Laguna Pes; Jean de la Rosette; Ton G van Leeuwen Journal: J Med Imaging (Bellingham) Date: 2015-07-09
Authors: Mieke T J Bus; Paul Cernohorsky; Daniel M de Bruin; Sybren L Meijer; Geert J Streekstra; Dirk J Faber; Guido M Kamphuis; Patricia J Zondervan; Marcel van Herk; Maria P Laguna Pes; Maik J Grundeken; Martin J Brandt; Theo M de Reijke; Jean J M C H de la Rosette; Ton G van Leeuwen Journal: J Med Imaging (Bellingham) Date: 2018-02-12
Authors: Dimitri Barski; Holger Gerullis; Evangelos Georgas; Andreas Bär; Bernhard Lammers; Albert Ramon; Dirk Ysebaert; Bernd Klosterhalfen; Mihaly Boros; Thomas Otto Journal: Biomed Res Int Date: 2014-09-16 Impact factor: 3.411
Authors: Holger Gerullis; Thorsten H Ecke; Dimitri Barski; Carsten Bantel; Andreas Weyland; Jens Uphoff; Thomas Jansen; Friedhelm Wawroschek; Alexander Winter Journal: J Int Med Res Date: 2017-02-13 Impact factor: 1.671
Authors: Abel Swaan; Christophe K Mannaerts; Matthijs Jv Scheltema; Jakko A Nieuwenhuijzen; C Dilara Savci-Heijink; Jean Jmch de la Rosette; R Jeroen A van Moorselaar; Ton G van Leeuwen; Theo M de Reijke; Daniel Martijn de Bruin Journal: JMIR Res Protoc Date: 2018-05-21
Authors: Massimo Valerio; Hashim U Ahmed; Mark Emberton; Nathan Lawrentschuk; Massimo Lazzeri; Rodolfo Montironi; Paul L Nguyen; John Trachtenberg; Thomas J Polascik Journal: Eur Urol Date: 2013-06-06 Impact factor: 20.096